PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16082424-0	2005	Polymorphic variants of the beta2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population.	Propranolol	85-95	adrenoceptor beta 2	Homo sapiens	71-76	
18222471-5	2008	Receptor stability in detergent solution was studied by isothermal denaturation, and it was found that the E122W and E122Y mutations enhanced the beta(2)AR thermal half-life by 9.3- and 6.7-fold, respectively, at 37 degrees C. The beta(1)AR was also stabilized by the introduction of tryptophan at Glu147(3.41), and the effect on protein behavior was similar to the rescue of the unstable wild-type receptor by the antagonist propranolol.	Propranolol	426-437	adrenoceptor beta 2	Homo sapiens	146-155	
16177222-5	2006	SR 59119A-induced relaxation was unaffected by the blockade of ADRB1 and ADRB2 by 0.1 microM propranolol but was significantly decreased by the blockade of ADRB1, ADRB2, and ADRB3 by 10 microM propranolol.	Propranolol	193-204	adrenoceptor beta 2	Homo sapiens	163-168	
16374847-0	2006	Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis.	Propranolol	89-100	adrenoceptor beta 2	Homo sapiens	13-39	
16374847-3	2006	We hypothesized that gene polymorphisms at the beta2-AR may influence the hemodynamic response to propranolol in patients with cirrhosis.	Propranolol	98-109	adrenoceptor beta 2	Homo sapiens	47-55	
16335946-3	2005	This inhibition was counteracted by addition of the beta(2)-AR antagonist propranolol (LZP).	Propranolol	74-85	adrenoceptor beta 2	Homo sapiens	52-62	
16082424-4	2005	To examine the association between the Gln27Glu polymorphism of the ADRB2 gene and dyslipidemia induced by propranolol, we recruited 19 healthy individuals who were homozygous for either the Gln27 (wild-type, N = 11) or the Glu27 (homozygous mutant, N = 8) genotype.	Propranolol	107-118	adrenoceptor beta 2	Homo sapiens	68-73	
16082424-8	2005	Significant changes in physiological parameters (HR, SBP, DBP) have been found in association with ADRB2 variants in both native and mutant subgroups after propranolol intake.	Propranolol	156-167	adrenoceptor beta 2	Homo sapiens	99-104	
16082424-11	2005	The evidence that subjects homozygous for Gln27 in the ADRB2 gene show a significant reduction of HDL-CHO levels, as well as the increased TG levels in subjects homozygous for Glu27 after propranolol administration, suggest that the Gln27Glu polymorphism represents a risk factor for dyslipidemia induced by propranolol.	Propranolol	308-319	adrenoceptor beta 2	Homo sapiens	55-60	
15383152-10	2004	The enhancing effect of proatherogenic cytokine production by epinephrine was down regulated by the beta1 and beta2 adrenoceptor antagonist, propranolol, but not by the beta1 adrenoceptor antagonist, atenolol, suggesting the effect involved beta2 adrenoceptors.	Propranolol	141-152	adrenoceptor beta 2	Homo sapiens	110-128	
15595859-7	2004	Zonal displacement chromatography using CGP 12177A as the marker and racemic mixtures of the antagonists nadolol and propranolol demonstrated that the immobilized beta(2)-AR retained its ability to specifically bind these compounds.	Propranolol	117-128	adrenoceptor beta 2	Homo sapiens	163-173	
12732361-5	2003	The non-selective beta(1)-/-beta(2)-AR antagonists; propranolol and CGP 12177, at 10(-7)M, inhibited luciferase activity induced by these agonists by 80-96%.	Propranolol	52-63	adrenoceptor beta 2	Homo sapiens	28-38	
11159726-7	2001	The maximum extent of attenuation was RANTES > or = eotaxin > GM-CSF >> IL-8, and was prevented by either propranolol (1 microM), a non-selective beta-adrenoceptor antagonist, or ICI 118511 (IC(50) 15 nM), a selective beta(2)-adrenoceptor antagonist.	Propranolol	118-129	adrenoceptor beta 2	Homo sapiens	230-250	
12642394-6	2003	Addition of the beta-AR antagonist, propranolol, blocked the ADR-induced alpha(2A)-AR desensitization.	Propranolol	36-47	adrenoceptor beta 2	Homo sapiens	16-23	
12398570-8	2002	RESULTS: Compared with the ordinary dose of carvedilol 10 mg once a day, the improper regimen (10 mg after breakfast followed by 5 mg after lunch and dinner) increases the beta(2)-adrenoceptor binding occupancy at night (2300) to as high as the mean beta(2)-adrenoceptor binding occupancy after an ordinary dose of propranolol.	Propranolol	315-326	adrenoceptor beta 2	Homo sapiens	172-192	
10408809-12	1999	Furthermore, application of the beta2-adrenoreceptor antagonist propranolol prevented the decrease of lymphocytes and diminished the neutrophilia.	Propranolol	64-75	adrenoceptor beta 2	Homo sapiens	32-52	
9878881-14	1999	Blocking the sympathetic nervous system (SNS) transmission by application of the beta2-adrenoreceptor antagonist propranolol not only inhibited the increase but further downregulated the endotoxin induced IL-10 concentration in the media of whole blood cell cultures, whereas the TNF-alpha decrease was only partially prevented.	Propranolol	113-124	adrenoceptor beta 2	Homo sapiens	81-101	
8101966-1	1993	We previously reported that Asn312 of the beta 2-adrenergic receptor and Asn385 in the homologous position in the 5-hydroxytryptamine1A receptor are important for binding to a class of beta-adrenergic receptor antagonists including propranolol and alprenolol.	Propranolol	232-243	adrenoceptor beta 2	Homo sapiens	42-68	
9873044-9	1999	The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation.	Propranolol	144-155	adrenoceptor beta 2	Homo sapiens	19-27	
9873044-9	1999	The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation.	Propranolol	144-155	adrenoceptor beta 2	Homo sapiens	100-108	
9873044-9	1999	The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation.	Propranolol	144-155	adrenoceptor beta 2	Homo sapiens	100-108	
7476903-5	1995	Thus, the beta 2-adrenoceptor agonists albuterol and procaterol partially (approximately 40%) suppressed TNF-alpha generation in a propranolol-sensitive manner.	Propranolol	131-142	adrenoceptor beta 2	Homo sapiens	10-29	
9050006-12	1997	The beta-AR ligands isoprenaline and propranolol showed affinities expected for functional beta 2-ARs.	Propranolol	37-48	adrenoceptor beta 2	Homo sapiens	4-11	
7600375-6	1995	The potentiating effect of salbutamol on IgE production was blocked by two antagonists of beta 2-adrenoceptor, namely butoxamine and D,L-propranolol, suggesting a beta-adrenoceptor-mediated event.	Propranolol	133-148	adrenoceptor beta 2	Homo sapiens	90-109	
8392360-2	1993	A double-blind placebo-controlled study was conducted on the effects of oral terbutaline (beta 2-adrenoceptor agonist) and propranolol (beta 1 beta 2-adrenoceptor antagonist) on basal heat production of skeletal muscle, measured ex vivo by direct microcalorimetry.	Propranolol	123-134	adrenoceptor beta 2	Homo sapiens	143-162	
1845926-9	1991	The ability of propranolol but not atenolol to block this change suggests that the acute decrease in K+ levels was due to beta 2-adrenergic receptor stimulation.	Propranolol	15-26	adrenoceptor beta 2	Homo sapiens	122-148	
8157045-1	1993	A double blind placebo-controlled study was conducted of the effects of oral propranolol (beta 1 beta 2-adrenoceptor antagonist) and terbutaline (beta 2-adrenoceptor agonist) on erythrocyte heat production, measured by direct microcalorimetry under static conditions at 37 degrees C and pH 7.4.	Propranolol	77-88	adrenoceptor beta 2	Homo sapiens	97-116	
2169833-3	1990	We also studied the affinity of human lymphocyte beta 2-adrenoceptor for (+)-sotalol, (-)-sotalol, and (+/-)-propranolol.	Propranolol	103-120	adrenoceptor beta 2	Homo sapiens	49-68	
2169833-14	1990	The affinity of the human lymphocyte beta 2-adrenoceptor was approximately 60-fold greater for (-)-sotalol (Ki, 108 +/- 12 nM) than for (+)-sotalol (Ki, 6,410 +/- 1,020 nM), and approximately 20,000-fold greater for (+/-)-propranolol (Ki, 0.33 +/- 0.08 nM) than for (+)-sotalol.	Propranolol	216-233	adrenoceptor beta 2	Homo sapiens	37-56	
34417358-7	2021	We found that intra-dDG infusions of ISO given prior to retrieval caused deficits in working and reference memory which was blocked by pretreatment with the BAR-antagonist, propranolol (PRO).	Propranolol	173-184	adrenoceptor beta 2	Homo sapiens	157-160	
34650198-8	2021	RESULTS: In propranolol-treated HMC-1s, the expressions of ADRB1 (beta1-AR) and ADRB2 (beta2-AR) were reduced by 70% and 60%, respectively, and that of cytokines and mediators were reduced.	Propranolol	12-23	adrenoceptor beta 2	Homo sapiens	80-85	
34650198-10	2021	However, propranolol can work well in shRNA-ADRB1 or shRNA-ADRB2 transfected HMC-1s.	Propranolol	9-20	adrenoceptor beta 2	Homo sapiens	59-64	
34650198-11	2021	CONCLUSIONS: Propranolol inhibit the proliferation of HemECs and promote their apoptosis and autophagy through acting on both beta1 and beta2 adrenoceptor in mast cell.	Propranolol	13-24	adrenoceptor beta 2	Homo sapiens	136-154	
34650198-14	2021	Propranolol can work well in shRNA-ADRB1 or shRNA-ADRB2 transfected HMC-1s.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	50-55	
34417358-7	2021	We found that intra-dDG infusions of ISO given prior to retrieval caused deficits in working and reference memory which was blocked by pretreatment with the BAR-antagonist, propranolol (PRO).	Propranolol	186-189	adrenoceptor beta 2	Homo sapiens	157-160	
34309518-10	2021	Small skin arteries and arterioles, pre-treated with prazosin and stimulated with NE, exhibited ADRB2-mediated vasodilation, which was inhibited by the beta blockers, propranolol or timolol.	Propranolol	167-178	adrenoceptor beta 2	Homo sapiens	96-101	
34638341-0	2021	Beta 2 Adrenergic Receptor Antagonist Propranolol and Opioidergic Receptor Antagonist Naltrexone Produce Synergistic Effects on Breast Cancer Growth Prevention by Acting on Cancer Cells and Immune Environment in a Preclinical Model of Breast Cancer.	Propranolol	38-49	adrenoceptor beta 2	Homo sapiens	0-26	
2907348-3	1988	A more detailed analysis revealed that all beta-adrenoceptor antagonists increased right atrial beta 1-adrenoceptor density, but right atrial beta 2-adrenoceptor density was increased only in the sotalol/propranolol group, remaining unchanged in the metoprolol and atenolol groups, and was decreased in the pindolol group.	Propranolol	204-215	adrenoceptor beta 2	Homo sapiens	142-161	
35163250-3	2022	In the present study, we wanted to look deep into the effects of the ADRB2 blockers propranolol and ICI-118,551 on two main aspects of cancer progression: (i) the changes on the inflammatory response of ccRCC cells; and (ii) the modulation on the Warburg effect (glycolytic metabolism), concretely, on the expression of genes involved in the cell reactive oxygen species (ROS) balance and levels.	Propranolol	84-95	adrenoceptor beta 2	Homo sapiens	69-74	
2885202-6	1987	Lymphocyte beta 2-adrenoceptor number increased significantly following propranolol treatment, but not after oxprenolol for atenolol.	Propranolol	72-83	adrenoceptor beta 2	Homo sapiens	11-30	
2902891-9	1988	Similarly, in corresponding lymphocytes, only sotalol or propranolol increased beta 2-adrenoceptor density, while metoprolol and atenolol did not affect it and pindolol decreased it.	Propranolol	57-68	adrenoceptor beta 2	Homo sapiens	79-98	
2902891-7	1988	All beta-adrenoceptor antagonists increased right atrial beta 1-adrenoceptor density; on the other hand, only sotalol and propranolol also increased right atrial beta 2-adrenoceptor density, whereas metoprolol and atenolol did not affect it and pindolol decreased it.	Propranolol	122-133	adrenoceptor beta 2	Homo sapiens	162-181	
2839668-5	1988	After propranolol administration, in vitro beta-1 and beta-2 adrenoceptor occupancy declined from initially 97% to less than 10% within 48 hr.	Propranolol	6-17	adrenoceptor beta 2	Homo sapiens	54-73	
2873850-1	1986	A short-term effect of propranolol on beta 2-adrenoceptor density in mononuclear lymphocytes was studied in 15 male patients with essential hypertension.	Propranolol	23-34	adrenoceptor beta 2	Homo sapiens	38-57	
2439825-5	1986	Propranolol treatment (4 X 40 mg/day) increased the density of beta 2-adrenoceptors by 25% after 2 days; during treatment beta 2-adrenoceptor density remained elevated.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	63-82	
2439825-0	1986	Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes.	Propranolol	10-21	adrenoceptor beta 2	Homo sapiens	63-82	
2427860-2	1986	Propranolol (unselective; no ISA; 4 X 40 mg/day) increased beta 2-adrenoceptor density by 25-40%; after withdrawal beta 2-adrenoceptor density declined slowly, being still elevated for 3 days.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	59-78	
2875397-5	1986	The decrease in lymphocyte beta 2-adrenoceptor density induced by pindolol could be completely prevented by simultaneous administration of propranolol (3 X 40 mg/day) indicating that the PAA of pindolol is the cause of its beta-adrenoceptor decreasing effect.	Propranolol	139-150	adrenoceptor beta 2	Homo sapiens	27-46	
2439825-6	1986	After withdrawal of propranolol, beta 2-adrenoceptor density declined slowly, being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h, though heart rate was significantly increased.	Propranolol	20-31	adrenoceptor beta 2	Homo sapiens	33-52	
33558238-7	2021	Our functional protein association networks analysis and knockdown of ADRB2 and AQP1 indicated that propranolol treatment and AQP1 down-regulation trigger the same pathway, suggesting that AQP1 is a major driver of beta-blocker antitumor response.	Propranolol	100-111	adrenoceptor beta 2	Homo sapiens	70-75	
6203844-4	1984	Propranolol, a competitive antagonist of beta 2-adrenergic receptor, blocks the inhibition of release and the cAMP accumulation caused by fenoterol.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	41-67	
6849742-7	1983	6 The measurement of forearm blood flow following intravenous bolus injections of isoprenaline provides useful information about the beta 2-adrenoceptor antagonism of propranolol and practolol.	Propranolol	167-178	adrenoceptor beta 2	Homo sapiens	133-152	
16716-0	1977	Beta-2 adrenoceptor blocking activity of penbutolol and propranolol at very low doses.	Propranolol	56-67	adrenoceptor beta 2	Homo sapiens	0-19	
2856815-3	1985	This effect appears to be mediated by beta 2-adrenoceptor stimulation, since the exercise-induced increase in beta 2-adrenoceptor density was markedly attenuated by pretreatment of the volunteers with propranolol (5 mg intravenously 45 min before exercise), but not by pretreatment with the beta 1-selective antagonist bisoprolol (2.5 mg intravenously 30 min before exercise).	Propranolol	201-212	adrenoceptor beta 2	Homo sapiens	38-57	
2856815-3	1985	This effect appears to be mediated by beta 2-adrenoceptor stimulation, since the exercise-induced increase in beta 2-adrenoceptor density was markedly attenuated by pretreatment of the volunteers with propranolol (5 mg intravenously 45 min before exercise), but not by pretreatment with the beta 1-selective antagonist bisoprolol (2.5 mg intravenously 30 min before exercise).	Propranolol	201-212	adrenoceptor beta 2	Homo sapiens	110-129	
6134510-8	1983	Beta-blockers, particularly propranolol and metoprolol, with which we have the most experience, work via beta 2 adrenoceptor blockade in the heart.	Propranolol	28-39	adrenoceptor beta 2	Homo sapiens	105-124	
31709066-4	2019	The method was applied to the human beta2-adrenergic receptor, resulting in eight room-temperature co-crystal structures with six different ligands, including previously unreported structures with carvedilol and propranolol.	Propranolol	212-223	adrenoceptor beta 2	Homo sapiens	36-61	
32854260-9	2020	In summary, propranolol and ICI-118,551 have shown antitumor benefits in VHL-derived ccRCC, and since ccRCCs comprise 63% of the total RCCs, targeting ADRB2 becomes a promising drug for VHL and other non-VHL tumors.	Propranolol	12-23	adrenoceptor beta 2	Homo sapiens	151-156	
30871232-2	2019	Yet even in tumors with active ADRB2 signaling propranolol may be ineffective.	Propranolol	47-58	adrenoceptor beta 2	Homo sapiens	31-36	
31624248-9	2019	These effects were reversed by the ADRB antagonists propranolol and ICI118,551 (an ADRB2-specific antagonist).	Propranolol	52-63	adrenoceptor beta 2	Homo sapiens	83-88	
31296894-4	2019	Propranolol, a non-specific beta1-and beta2-adrenergic receptor antagonist, was recently designated as the first therapeutic (orphan) drug for VHL disease.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	38-63	
30871232-5	2019	Therefore, a comprehensive analysis of ADRB2 signaling in the context of other signaling mechanisms is necessary to identify patients who will benefit from propranolol therapy.	Propranolol	156-167	adrenoceptor beta 2	Homo sapiens	39-44	
30871232-6	2019	This review discusses how information on the antiapoptotic mechanisms activated by ADRB2 can guide clinical trials of ADRB2 antagonist propranolol as potential life-extending therapy for prostate cancer.	Propranolol	135-146	adrenoceptor beta 2	Homo sapiens	83-88	
30871232-6	2019	This review discusses how information on the antiapoptotic mechanisms activated by ADRB2 can guide clinical trials of ADRB2 antagonist propranolol as potential life-extending therapy for prostate cancer.	Propranolol	135-146	adrenoceptor beta 2	Homo sapiens	118-123	
30225948-1	2018	OBJECTIVE: A recent study observed a 2-fold greater risk of Parkinson disease (PD) in relation to the beta2-adrenoreceptor antagonist propranolol and a markedly lower risk of PD for the beta2-adrenoreceptor agonist salbutamol.	Propranolol	134-145	adrenoceptor beta 2	Homo sapiens	102-122	
30325031-4	2019	The order of Kb values between drugs such as adrenaline hydrochloride, norepinephrine bitartrate, and propranolol hydrochloride with beta2 -AR is well consistent with that reported in the literature.	Propranolol	102-127	adrenoceptor beta 2	Homo sapiens	133-142	
29472588-6	2018	We further show a clear role of both the cell membrane and the beta2-adrenoceptor in determining high local BY-propranolol concentrations at the cell surface.	Propranolol	111-122	adrenoceptor beta 2	Homo sapiens	63-81	
29515233-9	2018	We suggest that blocking beta2AR with propranolol or inhibiting FAK activation with PF562 271 may be novel strategies for depressed patients with invasive prostate cancer.	Propranolol	38-49	adrenoceptor beta 2	Homo sapiens	25-32	
27133786-8	2016	The beta1-AR/beta2-AR inhibitor propranolol reduced the numbers of the neutrophils in the circulation, suppressed neutrophil infiltration into colonic tissues, and attenuated the colonic tissue damage promoted by chronic stress.	Propranolol	32-43	adrenoceptor beta 2	Homo sapiens	13-21	
28240622-2	2017	Propranolol, a nonselective beta1, beta2-adrenergic receptor antagonist, reduces resting heart rate and cardiac work caused by elevated circulating catecholamines.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	35-60	
28721035-5	2017	beta2R antagonism by propranolol or ICI 118.551 (10-12-10-4 M) resulted in concentration-dependent inhibition of VI-induced cAMP production, and ICI 118.551 was more potent.	Propranolol	21-32	adrenoceptor beta 2	Homo sapiens	0-6	
27668163-1	2016	beta Blockers such as propranolol and labetalol are known to induce toxic myopathy because of their partial beta2 adrenoceptor agonistic effect.	Propranolol	22-33	adrenoceptor beta 2	Homo sapiens	108-126	
26574555-11	2016	We have thus demonstrated that propranolol acts on HemSCs in IH to suppress proliferation and promote apoptosis in a dose-dependent fashion via beta2AR perturbation, resulting in reduced cAMP and MAPK activation.	Propranolol	31-42	adrenoceptor beta 2	Homo sapiens	144-151	
27035124-9	2016	Propranolol decreased beta2-adrenergic receptor-activated invasion.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	22-47	
26489037-0	2016	Influence of CYP2D6 and beta2-adrenergic receptor gene polymorphisms on the hemodynamic response to propranolol in Chinese Han patients with cirrhosis.	Propranolol	100-111	adrenoceptor beta 2	Homo sapiens	24-49	
26489037-2	2016	This study is to evaluate the relationship between CYP2D6 and beta2-adrenergic receptor (beta2-AR) gene polymorphisms and the hemodynamic response to propranolol in Chinese Han patients.	Propranolol	150-161	adrenoceptor beta 2	Homo sapiens	62-87	
26489037-2	2016	This study is to evaluate the relationship between CYP2D6 and beta2-adrenergic receptor (beta2-AR) gene polymorphisms and the hemodynamic response to propranolol in Chinese Han patients.	Propranolol	150-161	adrenoceptor beta 2	Homo sapiens	89-97	
27094283-5	2016	Here, we present a standard computational protocol to evaluate the binding properties of the two enantiomers of the non-selective beta-blocker propanolol in the beta2 adrenergic receptor"s binding site.	Propranolol	143-153	adrenoceptor beta 2	Homo sapiens	161-186	
26574555-9	2016	A selective beta2AR antagonist mirrored propranolol"s effects on HemSCs in a dose-dependent fashion, and a selective beta1AR antagonist had no effect, supporting a role for beta2AR signaling in IH pathobiology.	Propranolol	40-51	adrenoceptor beta 2	Homo sapiens	12-19	
26574555-16	2016	Furthermore, propranolol acts via perturbation of beta2AR, and not beta1AR, although both receptors are expressed in HemSCs.	Propranolol	13-24	adrenoceptor beta 2	Homo sapiens	50-57	
26109805-0	2015	beta-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis.	Propranolol	61-72	adrenoceptor beta 2	Homo sapiens	0-26	
26058426-8	2015	Altogether these data suggest that beta2-AR plays an important role in prostate cancer metastasis formation and that the treatment with antagonist propanolol, could represents an interesting tool to control this process in cells overexpressing beta2AR.	Propranolol	147-157	adrenoceptor beta 2	Homo sapiens	244-251	
26109805-1	2015	AIM: To evaluate the association of beta-2 adrenergic receptor (beta2-AR) gene polymorphism with response of variceal pressure to propranolol in cirrhosis.	Propranolol	130-141	adrenoceptor beta 2	Homo sapiens	36-62	
26109805-1	2015	AIM: To evaluate the association of beta-2 adrenergic receptor (beta2-AR) gene polymorphism with response of variceal pressure to propranolol in cirrhosis.	Propranolol	130-141	adrenoceptor beta 2	Homo sapiens	64-72	
26109805-6	2015	CONCLUSION: The variceal pressure response to propranolol was associated with polymorphism of beta2-AR gene.	Propranolol	46-57	adrenoceptor beta 2	Homo sapiens	94-102	
24837703-11	2014	Consistently, in the presence of propranolol (10(-6)M), a beta-AR blocker, the arterenol (10(-8)M) effects on thymocytes were augmented.	Propranolol	33-44	adrenoceptor beta 2	Homo sapiens	63-65	
25323788-5	2014	The inflammatory-related cytokines interleukin (IL)-1beta, IL-6 and IL-8 were detected after pretreatment with the alpha1/beta2-AR blockers phentolamine/propranolol, both in vitro and in vivo.	Propranolol	153-164	adrenoceptor beta 2	Homo sapiens	115-130	
25523517-2	2015	The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis.	Propranolol	16-27	adrenoceptor beta 2	Homo sapiens	47-55	
25523517-2	2015	The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis.	Propranolol	190-201	adrenoceptor beta 2	Homo sapiens	47-55	
25026350-1	2014	CONTEXT: Propranolol, atenolol, and ICI118,551 are non-selective beta-adrenergic receptor (AR), beta1-AR, and beta2-AR antagonists, respectively.	Propranolol	9-20	adrenoceptor beta 2	Homo sapiens	110-118	
24933041-5	2014	In particular, the beta2-AR seems to be the mostly involved in these responses, and the beta1-/beta2-AR blocker propranolol results highly effective in inhibiting both the increase of VEGF expression caused by a hypoxic insult and the consequent neovascular response.	Propranolol	112-123	adrenoceptor beta 2	Homo sapiens	95-103	
24905583-4	2014	NCI-H292 epithelial cell line was used to determine the contribution of beta2-AR signaling to CSE-induced MUC5AC production by treatment with beta2-AR antagonists propranolol and ICI118551 and beta2-AR-targeted small interfering RNA.	Propranolol	163-174	adrenoceptor beta 2	Homo sapiens	72-80	
24905583-4	2014	NCI-H292 epithelial cell line was used to determine the contribution of beta2-AR signaling to CSE-induced MUC5AC production by treatment with beta2-AR antagonists propranolol and ICI118551 and beta2-AR-targeted small interfering RNA.	Propranolol	163-174	adrenoceptor beta 2	Homo sapiens	142-150	
24905583-4	2014	NCI-H292 epithelial cell line was used to determine the contribution of beta2-AR signaling to CSE-induced MUC5AC production by treatment with beta2-AR antagonists propranolol and ICI118551 and beta2-AR-targeted small interfering RNA.	Propranolol	163-174	adrenoceptor beta 2	Homo sapiens	142-150	
24554803-5	2013	RESULTS: Results gained shows that following the blockade of beta-2 adrenergic receptor with Propranolol (20 mg-aerosol), stimulation of alpha adrenergic receptor with Oxedrine (120 mg-aerosol) and blockage of these receptors with Tolazoline (20 mg-aerosol), does not change significantly the bronchomotor tonus of the tracheobronchial tree (p > 0.1).	Propranolol	93-104	adrenoceptor beta 2	Homo sapiens	61-87	
24214595-5	2013	Adding of beta2AR antagonist propranolol to the Jurkat cells pre-incubated with isoproterenol didn"t change expression of IL-2.	Propranolol	29-40	adrenoceptor beta 2	Homo sapiens	10-17	
24214595-6	2013	beta2AR antagonist propranolol induced slight increase of IL-2 expression in PHA-stimulated Jurkat cells pre-incubated with isoproterenol.	Propranolol	19-30	adrenoceptor beta 2	Homo sapiens	0-7	
24214595-10	2013	Propranolol prevented increase of IL-10 expression in the PHA-stimulated Jurkat cells pre-incubated with beta2AR agonist.	Propranolol	0-11	adrenoceptor beta 2	Homo sapiens	105-112	
23186269-10	2012	The beta2AR blocker propranolol abrogated the growth inhibitory effect of formoterol.	Propranolol	20-31	adrenoceptor beta 2	Homo sapiens	4-11	
22743651-3	2012	In a prior report, we identified expression of beta2-AR (B2-AR) and its phosphorylated form (B2-ARP) in a case of infantile hemangioma that responded to propranolol treatment.	Propranolol	153-164	adrenoceptor beta 2	Homo sapiens	47-55	
22743651-3	2012	In a prior report, we identified expression of beta2-AR (B2-AR) and its phosphorylated form (B2-ARP) in a case of infantile hemangioma that responded to propranolol treatment.	Propranolol	153-164	adrenoceptor beta 2	Homo sapiens	57-62	
22133559-7	2012	A recent study showed that propranolol, a beta adrenergic receptor (beta-AR) antagonist, was effective as treatment for infantile hemangioma.	Propranolol	27-38	adrenoceptor beta 2	Homo sapiens	68-75